. 2020 Apr 26;31(6):1025–1048. doi: 10.1007/s00198-020-05384-2

Table 4.

BCT monitoring studies (13 total) for drug or other treatments. Non-opportunistic BCT was performed at the hip (H) or spine (S) or at both sites. N = 1644 subjects total, over all studies. Details of the studies in italicized entries are discussed in Appendix D

Study	Age (years) mean ± SD	Number	Hip or spine assessed	Treatment
Keaveny 2007 [82]	62.5 ± 1.6	25	S	Alendronate
Keaveny 2007 [82]	64.5 ± 1.4	28	S	Teriparatide
Mawatari 2008 [83]	62.7 ± 2.2	15	S	Control (non-antiresorptive)
Mawatari 2008 [83]	60.4 ± 2.9	14	S	Alendronate
Keaveny 2008 [84]	55–85	72	H	PTH(1–84)
	55–85	42	H	Alendronate
	55–85	37	H	PTH(1–84) and alendronate
Lewiecki 2009 [85]	63.5 ± 6.0	46	H + S	Placebo
Lewiecki 2009 [85]	64.8 ± 7.2	47	H + S	Ibandronate
Keaveny 2012 [86]	64.2 ± 7.7	27	H	Teriparatide
Keaveny 2012 [86]	62.2 ± 8.4	21	H	Alendronate
Brixen 2013[87]	64.0 ± 6.2	105	H + S	Placebo
Brixen 2013[87]	63.9 ± 7.3	109	H + S	Odanacatib
Cosman 2013 [88]	67.9 ± 1.3	43	H + S	Raloxifene, add teriparatide
	68.6 ± 1.3	44	H + S	Raloxifene, switch to teriparatide
	67.1 ± 1.3	46	H + S	Alendronate, add teriparatide
	69.3 ± 1.2	49	H + S	Alendronate, switch to teriparatide
Keaveny 2014 [31]	74.1 ± 6.0	48	H + S	Placebo
Keaveny 2014 [31]	73.3 ± 4.2	51	H + S	Denosumab
Kleerekoper 2014 [89]	62 ± 8	34	H + S	Teriparatide
Snyder 2017[90]^†	72.4 ± 5.5	101	H + S	Placebo
Snyder 2017[90]^†	72.3 ± 6.3	110	H + S	Testosterone
Keaveny 2017 [91]	64.3 ± 4.7	24	H + S	Romosozumab
	65.8 ± 5.7	31	H + S	Teriparatide
	66.1 ± 5.8	27	H + S	Placebo
Langdahl 2017[92]	71.8 ± 7.4	218	H	Romosozumab (prior bisphosphonate)
Langdahl 2017[92]	71.2 ± 7.7	218	H	Teriparatide (prior bisphosphonate)
Howe 2019 [93]	56–89	12	H	AGN1 LOEP

VirtuOst or a related software implementation of BCT was used in all studies

^†Women in all studies except Snyder [90], in which only men were assessed